Corcept Therapeutics Incorporated announced completion of enrollment in CATALYST, a Phase 4 trial examining the prevalence of hypercortisolism (Cushing?s syndrome) in patients with difficult-to-control type 2 diabetes; patients with hypercortisolism may enter a randomized, placebo-controlled study of Korlym®. CATALYST is a prospective, Phase 4 study with two parts. The prevalence phase assesses the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes, which the study defines as hemoglobin A1c greater than 7.5% despite receiving optimal treatment.

Patients from this group with a dexamethasone suppression test value greater than 1.8 µg/dL and dexamethasone levels greater than 140 ng/dL are identified as having hypercortisolism. Subject to satisfying additional screening criteria, these patients are eligible to enter CATALYST?s treatment phase, in which they are randomized, 2:1, to receive treatment with either Korlym or placebo for 24 weeks. CATALYST is being conducted at 35 sites in the United States.